Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03866577
Recruitment Status : Terminated (Study was terminated based on Sponsor decision.)
First Posted : March 7, 2019
Last Update Posted : August 9, 2021
Sponsor:
Information provided by (Responsible Party):
Momenta Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics of the drug will be measured as platelet response in patients with ITP.

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenic Purpura (ITP) Biological: Biological: M254 Drug: Placebo Biological: Intravenous immunoglobulin (IVIg) Phase 1 Phase 2

Detailed Description:
The Part A of the study is currently not accepting healthy volunteers as the recruitment for the part A has completed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Masking Description:

Part A: Double (Subject, Investigator);

Part B, C, and D: Open Label Investigations

Primary Purpose: Treatment
Official Title: A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Actual Study Start Date : December 21, 2018
Actual Primary Completion Date : June 9, 2021
Actual Study Completion Date : June 9, 2021


Arm Intervention/treatment
Experimental: Part A
Healthy volunteers will receive a single ascending dose of M254 or placebo
Biological: Biological: M254
M254 administered as intravenous infusion

Drug: Placebo
Placebo administered as intravenous infusion

Experimental: Part B
Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg
Biological: Biological: M254
M254 administered as intravenous infusion

Biological: Intravenous immunoglobulin (IVIg)
IVIg administered as intravenous infusion

Experimental: Part C
ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later
Biological: Biological: M254
M254 administered as intravenous infusion

Biological: Intravenous immunoglobulin (IVIg)
IVIg administered as intravenous infusion

Experimental: Part D
ITP patients will receive repeated doses of M254
Biological: Biological: M254
M254 administered as intravenous infusion




Primary Outcome Measures :
  1. Number and Severity of Adverse Events (AEs) - Part A [ Time Frame: Up to approximately Day 29 ]
  2. Frequency of Clinically Significant Abnormalities in Clinical Safety Laboratory Values - Part A [ Time Frame: Up to approximately Day 29 ]
  3. Shift From Baseline in Clinically Significant Abnormalities for Clinical Safety Laboratory Values - Part A [ Time Frame: Up to approximately Day 29 ]
  4. Frequency of Clinically Significant Abnormalities in Vital Signs - Part A [ Time Frame: Up to approximately Day 29 ]
  5. Shift From Baseline in Clinically Significant Abnormalities for Vital Signs - Part A [ Time Frame: Up to approximately Day 29 ]
  6. Frequency of Clinically Significant Abnormalities in Electrocardiograms (ECGs) - Part A [ Time Frame: Up to approximately Day 29 ]
  7. Shift From Baseline in Clinically Significant Abnormalities for Electrocardiograms (ECGs) - Part A [ Time Frame: Up to approximately Day 29 ]
  8. Number and Severity of AEs - Part B [ Time Frame: Up to approximately Day 29 ]
  9. Frequency of Clinically Significant Abnormalities in Clinical Safety Laboratory Values - Part B [ Time Frame: Up to approximately Day 29 ]
  10. Shift From Baseline in Clinically Significant Abnormalities for Clinical Safety Laboratory Values - Part B [ Time Frame: Up to approximately Day 29 ]
  11. Frequency of Clinically Significant Abnormalities in Vital Signs - Part B [ Time Frame: Up to approximately Day 29 ]
  12. Shift From Baseline in Clinically Significant Abnormalities for Vital Signs - Part B [ Time Frame: Up to approximately Day 29 ]
  13. Frequency of Clinically Significant Abnormalities in ECGs - Part B [ Time Frame: Up to approximately Day 29 ]
  14. Shift From Baseline in Clinically Significant Abnormalities for ECGs - Part B [ Time Frame: Up to approximately Day 29 ]
  15. Number and Severity of AEs - Part C [ Time Frame: Up to approximately Day 29 ]
  16. Frequency of Clinically Significant Abnormalities in Clinical Safety Laboratory Values - Part C [ Time Frame: Up to approximately Day 29 ]
  17. Shift From Baseline in Clinically Significant Abnormalities for Clinical Safety Laboratory Values - Part C [ Time Frame: Up to approximately Day 29 ]
  18. Frequency of Clinically Significant Abnormalities in Vital Signs - Part C [ Time Frame: Up to approximately Day 29 ]
  19. Shift From Baseline in Clinically Significant Abnormalities for Vital Signs - Part C [ Time Frame: Up to approximately Day 29 ]
  20. Frequency of Clinically Significant Abnormalities in ECGs - Part C [ Time Frame: Up to approximately Day 29 ]
  21. Shift From Baseline in Clinically Significant Abnormalities for ECGs - Part C [ Time Frame: Up to approximately Day 29 ]
  22. Measurement of Changes in Platelet Counts After M254 Administration Compared to IVIg - Part C [ Time Frame: Baseline to approximately Day 29 ]
  23. Number and Severity of AEs - Part D [ Time Frame: Up to approximately Day 71 ]
  24. Frequency of Clinically Significant Abnormalities in Clinical Safety Laboratory Values - Part D [ Time Frame: Up to approximately Day 71 ]
  25. Shift From Baseline in Clinically Significant Abnormalities for Clinical Safety Laboratory Values - Part D [ Time Frame: Up to approximately Day 71 ]
  26. Frequency of Clinically Significant Abnormalities in Vital Signs - Part D [ Time Frame: Up to approximately Day 71 ]
  27. Shift From Baseline in Clinically Significant Abnormalities for Vital Signs - Part D [ Time Frame: Up to approximately Day 71 ]
  28. Frequency of Clinically Significant Abnormalities in ECGs - Part D [ Time Frame: Up to approximately Day 71 ]
  29. Shift From Baseline in Clinically Significant Abnormalities for ECGs - Part D [ Time Frame: Up to approximately Day 71 ]

Secondary Outcome Measures :
  1. Maximum Plasma Concentration (Cmax) of M254 - Part A, B, and C [ Time Frame: Day 1 to Day 29 ]
  2. Time to Maximum Plasma Concentration (Tmax) of M254 - Part A, B, and C [ Time Frame: Day 1 to Day 29 ]
  3. Area Under the Concentration-time Curve From Zero to Time of Last Measurable Concentration Area [AUC(0 last)] of M254 - Part A, B, and C [ Time Frame: Day 1 to Day 29 ]
  4. Area Under the Concentration-time Curve From Zero to Infinity [AUC(0 ∞)] of M254 - Part A, B, and C [ Time Frame: Day 1 to Day 29 ]
  5. Volume of Distribution (Vd) of M254 - Part A, B, and C [ Time Frame: Day 1 to Day 29 ]
  6. Clearance of Drug (CL) M254 - Part A, B, and C [ Time Frame: Day 1 to Day 29 ]
  7. Mean Residence Time (MRT) of M254 - Part A, B, and C [ Time Frame: Day 1 to Day 29 ]
  8. Apparent Terminal-phase Half-life (t½) of M254 - Part A, B, and C [ Time Frame: Day 1 to Day 29 ]
  9. Cmax of M254 - Part D [ Time Frame: Day 1 to Day 71 ]
  10. Tmax of M254 - Part D [ Time Frame: Day 1 to Day 71 ]
  11. AUC(0 last) of M254 - Part D [ Time Frame: Day 1 to Day 71 ]
  12. AUC(0 ∞) of M254 - Part D [ Time Frame: Day 1 to Day 71 ]
  13. Vd of M254 - Part D [ Time Frame: Day 1 to Day 71 ]
  14. CL of M254 - Part D [ Time Frame: Day 1 to Day 71 ]
  15. MRT of M254 - Part D [ Time Frame: Day 1 to Day 71 ]
  16. t½ of M254 - Part D [ Time Frame: Day 1 to Day 71 ]
  17. Measurements of Changes in Platelet Counts After M254 Administration - Part D [ Time Frame: Baseline to approximately Day 71 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Criteria for Healthy Volunteers: Subject must be between the ages of 18 and 55 years; healthy as indicated by medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead electrocardiogram, and all abnormal findings are assessed as not clinically significant by the Investigator; not pregnant or breastfeeding; and no other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate.

Key Criteria for Immune Thrombocytopenic Purpura (ITP) Patients: Patient must be aged ≥18 years and diagnosed with ITP at least 3 months prior to screening, stable maintenance therapy for at least 4 weeks prior to the first study visit, not pregnant or breastfeeding, and no other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03866577


Locations
Show Show 28 study locations
Sponsors and Collaborators
Momenta Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Momenta General Queries Momenta Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Momenta Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03866577    
Other Study ID Numbers: CR108979
2018-003534-32 ( EudraCT Number )
MOM-M254-001 ( Other Identifier: Momenta Pharmaceuticals, Inc. )
First Posted: March 7, 2019    Key Record Dates
Last Update Posted: August 9, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Momenta Pharmaceuticals, Inc.:
Immune thrombocytopenic purpura
Healthy subjects
M254
Intravenous immunoglobulin (IVIg)
Additional relevant MeSH terms:
Layout table for MeSH terms
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Thrombotic Microangiopathies
Thrombocytopenia
Blood Platelet Disorders
Immune System Diseases
Hemorrhagic Disorders
Autoimmune Diseases
Immunoglobulins
Immunoglobulins, Intravenous
Antibodies
gamma-Globulins
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs